Search results: (10000)
News Is It Better to Switch or Cycle in the Treatment of Rheumatoid Arthritis?
The ideal strategy for treating rheumatoid arthritis is still the subject of research. We therefore present the results of a recent study comparing the impact of various therapeutic options when biological treatment is ineffective.
News Untreated Bleeding in Hemophilia A – An Underestimated Problem? To What Extent?
How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a recent study, the results of which were published in the journal Research and Practice in Thrombosis and Hemostasis.
News Treatment with Dupilumab in Severe Corticosteroid-Dependent Bronchial Asthma – A Case Study
We present the case of a 36-year-old woman with severe corticosteroid-dependent asthma with numerous comorbidities and complications due to long-term systemic corticosteroid therapy. Significant improvements in quality of life, asthma control, regression of skin changes in atopic dermatitis, and reduction in methylprednisolone consumption for this patient were only achieved after the initiation of biological treatment. Dupilumab, a monoclonal antibody against the α subunit of the receptor for interleukins IL-4 and IL-13, which is approved for the treatment of severe refractory eosinophilic bronchial asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis, was indicated in her treatment.
News Effectiveness of Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Clinical Practice
One of the new modalities for the treatment of ulcerative colitis (UC) is tofacitinib. Its effectiveness has already been demonstrated in clinical studies and is now being proven in real-world clinical practice, where we can evaluate the results of patients who could not be included in clinical trials or those with refractory disease.
News Increase in Thyroid Cancer Incidence Due to the Coronavirus Pandemic?
According to available data, COVID-19 disease does not worsen the course of thyroid cancer. However, the restriction of medical care during the pandemic is associated with concern about an increase in the incidence of this malignant disease and the associated morbidity and mortality.
News EAHAD 2024: Fresh results of paradigm5 and 6 studies confirm safety and efficacy of N9-GP
Nonacog beta pegol (N9-GP) is a recombinant factor IX with an extended half-life. Its properties allow for the maintenance of a satisfactorily high level of FIX with intravenous application once a week. At the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held in early February 2024 in Frankfurt, new findings on this treatment were presented during a satellite symposium by Novo Nordisk.
News Dabigatran Etexilate in the Treatment of Acute Thromboembolic Disease in Children
Until now, standard anticoagulants such as low-molecular-weight heparin or unfractionated heparin and others have been used in pediatric patients for the treatment of thromboembolism. The study presented below aimed to determine whether dabigatran could be the drug of the future in the treatment of pediatric patients with thromboembolism.
News HVD 2023: Cervical Cancer May Be the First Eliminated Malignancy. What Paths Will Lead to This Goal in the Czech Republic?
Cervical cancer is the 3rd most common cancer among women aged 15–44. Annually, it is diagnosed in 750–800 women in our country, and every 29 hours, one woman dies from it in the Czech Republic. However, it could become the first oncological disease that can be eliminated. How to achieve this was discussed by the chairman of the Czech Vaccinological Society ČLS JEP and Dean of the Faculty of Military Medicine at the University of Defense in Hradec Králové, Prof. MUDr. Roman Chlíbek, Ph.D., at a symposium supported by MSD during the October XVIII. Hradec Vaccinology Days (HVD).
News Clinical Profile and Outcomes of Patients with Cardiac Amyloidosis – Spanish Experience from Real Practice
Cardiac amyloidosis is caused by the deposition of amyloid fibrils in the myocardium and is among the diseases with significant diagnostic delay. Physicians from the University Hospital in Madrid shared their experiences with the diagnosis and treatment of these patients over the last decade in the cited work below.
News Direct Oral Anticoagulants and Their Reversal Agents – Current Options
In the last 10 years, the options for anticoagulant therapy have expanded with the introduction of direct oral anticoagulants (DOACs). It appears that DOACs may soon replace warfarin in the first line of prevention of venous thromboembolism, not only due to their clinical advantages but also thanks to newly available reversal agents that can be administered in case of major bleeding in patients taking DOACs. A recently published review article summarizes the current situation in this area.
News Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
Sotorasib is indicated as monotherapy for advanced non-small-cell lung cancer (NSCLC) with the KRASG12C gene mutation, if there has been progression after ≥ 1 prior line of systemic therapy. The 2-year analysis of data from the CodeBreaK 100 study published in April 2023 demonstrated the long-term benefit of sotorasib for this patient population in terms of progression-free survival (PFS) and overall survival (OS), regardless of programmed death-ligand 1 (PD-L1) receptor expression, including patients with a poor prognosis. In the Czech Republic, sotorasib has been reimbursed by public health insurance for this indication since September 2023.
News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy
Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.
News Options for Modifying and Improving the Efficiency of the HJHS Scoring System
The Hemophilia Joint Health Score (HJHS) is a validated tool for assessing joint health in individuals with hemophilia. Can it be modified to be used more effectively in clinical practice?
News Low-Molecular-Weight Heparin as Adjuvant Therapy in Small-Cell Lung Cancer − Results of the RASTEN Study
Several studies and meta-analyses in the past have pointed to a possible positive effect of low-molecular-weight heparins (LMWH) in the treatment of cancer. The RASTEN study therefore focused on the potential effect of enoxaparin in patients with small-cell lung cancer (SCLC).
News Safety of Dabigatran in Secondary Prevention of Venous Thromboembolism in Pediatric Patients
Low molecular weight heparin (LMWH) or warfarin (VKA – vitamin K antagonist) is typically used for the secondary prevention of venous thromboembolism. The DIVERSITY study extension examined the safety of dabigatran in this indication in pediatric patients.
News Does the type of oral anticoagulant affect heparin dosing during catheter ablation?
During catheter ablation, which patients undergo as part of atrial fibrillation (AF) treatment, current guidelines recommend the administration of heparin without interrupting oral anticoagulant therapy. A recently published analysis evaluated whether the type of oral anticoagulant affects the total dose of heparin administered during the ablation.
News 6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?
At this year's annual congress of the European Hematology Association (EHA), results from the analysis of 6-year data from the international randomized open-label phase III ECHELON-1 study on overall survival of patients with classical Hodgkin lymphoma (cHL) stage III/IV who received a combination of brentuximab vedotin with chemotherapy in the first-line treatment were presented, among other findings.
News Cenobamate in the Therapy of Pharmacoresistant Epilepsy in a Warfarinized Patient – A Case Study
A case study from Czech practice presents a patient with pharmacoresistant epilepsy and concurrent warfarin medication for heart valve replacement, where the INR value remained within the cardiologist’s recommended range without further adjustments to anticoagulant therapy during combined antiepileptic therapy with cenobamate (CNB) under the recommended dose titration.
News Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple pharmacokinetic protocol for patients with hemophilia A.
News Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
The possibility of actively preventing severe bleeding after a major cardiac surgical procedure using cardiopulmonary bypass (CPB) by administering a concentrate of activated procoagulant complex seems feasible, although a larger study will be needed to confirm its effect.
News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice
At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.